TuisAIM • NYSEAMERICAN
add
AIM ImmunoTech Inc
Vorige sluiting
$0,55
Dagwisseling
$0,54 - $0,61
Jaarwisseling
$0,53 - $20,33
Markkapitalisasie
4,85 m USD
Gemiddelde volume
6,69 m
P/V-verhouding
-
Dividend-opbrengs
-
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 21,00 k | -53,33% |
Bedryfskoste | 2,93 m | -50,23% |
Netto inkomste | -4,18 m | 30,03% |
Netto winsgrens | -19,88 k | -49,93% |
Wins per aandeel | -0,44 | 95,60% |
EBITDA | -2,91 m | 49,77% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 3,05 m | -23,38% |
Totale bates | 5,78 m | -32,83% |
Totale aanspreeklikheid | 15,56 m | 56,75% |
Totale ekwiteit | -9,78 m | — |
Uitstaande aandele | 8,15 m | — |
Prys om te bespreek | -0,17 | — |
Opbrengs op bates | -130,90% | — |
Opbrengs op kapitaal | 171,11% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -4,18 m | 30,03% |
Kontant van bedrywe | -1,99 m | 49,79% |
Kontant van beleggings | -95,00 k | -102,56% |
Kontant van finansiering | 2,72 m | 162,20% |
Netto kontantverandering | 638,00 k | -18,83% |
Beskikbare kontantvloei | -1,43 m | 74,40% |
Meer oor
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
The company has created an immunomodulatory double stranded RNA drug called Ampligen.
It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome. Wikipedia
Gestig
1966
Webwerf
Werknemers
22
